Last month, The Journal of Clinical Endocrinology and Metabolism published a classic congenital adrenal hyperplasia (CAH)-focused supplement, titled “Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime.” The supplement contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges...
Author: Derek Bagley
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves New Treatment Option For A Leading Cause of Diabetes-Related Blindness Genentech, a member of the Roche Group on February 4 announced that the U.S. Food and Drug Administration (FDA) approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of...
High Time: Addressing Research Gaps in Opioid-Associated Endocrine Conditions
Endocrine News speaks with Niki Karavitaki, MSc, PhD, FRCP, of the University of Birmingham, Birmingham Health Partners, and the University Hospitals Birmingham National Health Service Foundation Trust in Birmingham, U.K., chair of the Endocrine Society’s recent Scientific Statement on opioids’ impact on the endocrine system. She discusses gaps in research, as well as why healthcare...
Elizabeth Pearce, MD, MSc, discusses her ENDO 2024 presentation, which found that exposure to some endocrine-disrupting chemicals that harm the thyroid gland has increased over the past 20 years among U.S. women of childbearing age and pregnant women, especially among those with lower social and economic status. Elizabeth Pearce, MD, MSc, of the Boston University...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
Recipients of the Endocrine Society’s 2025 Edwin B. Astwood Award for Outstanding Research in Basic Science, David Mangelsdorf, PhD, and Steven Kliewer, PhD, have spent a lot of time in the lab with drunken mice. Find out how these besotted rodents may hold the secrets behind the evolution of how fibroblast growth factor 21 might... An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...
If it’s November, then it must be time for an issue of Endocrine News devoted entirely to the science and treatment of people living with diabetes to coincide with Diabetes Awareness Month in the United States. Each year we highlight the work of our members around the world and the research they conduct that contributes...